Note: Please read our disclaimer at the bottom of the article.
#StrongHands 🙌 #BOP 🚀 Nation Update ️️️️️️️️️️️️️️️️️️️❤️️
Hi, I’m Paul Mampilly.
Welcome to my company's Substack, where we provide daily coverage of #OGI (opportunity, growth, and innovation) market trends, macro level analysis, and stock picks.
Like our name suggests, at ATG Digital, we go Against the Grain to support everyday people on their investing journeys.
ATG also represents seeing the world for what is abundantly clear to see — an opportunity for incredible growth and the BRIGHT and PROSPEROUS future that lies ahead.
To aid you on your journey to financial freedom, we have five paid plans starting at $9.99 for you to consider.
With a subscription you get:
Premium Content: Weekly market and stock updates via email newsletter.
Stock Picking Guidance: Flash (buy/sell) alerts with targeted price points.
Model Portfolio Access: Access to LIVE portfolios.
Webinars: Private events with the team based on ideas preselected by you.
(Purple Tier Members)
Just visit atgdigital.media to see which plan is the best fit for your journey!
Substack 🥞 subscribers: 5,780
T-Shirt Giveaway! 🥳
Hey, everyone! Dean here with another ATG giveaway!
This time, we’re giving away one of our Bitcoin USD (BTC-USD) halving shirts to one lucky community member.
To be entered, all you have to do is like this post. Yup, that’s it — like this post. But . . .
If you want to increase your odds of winning, we’re also giving away one shirt in our Facebook Group and our X account, so be sure to follow us there and turn your notifications on!
This giveaway will end Thursday, April 25, and we’ll announce our Substack winner next Monday, April 29!
Dan: We’re Still Bullish 🐂 on Biotech
We’ve said it before, and we’ll say it again: The biotech industry has made incredible advancements over the last several years.
Despite this, overall market conditions have caused the companies in this sector to sell off . . .
However, innovation and growth continue!
And as market conditions ease and deflation and interest rate cuts unfold, biotech companies could be bid up tremendously!
Down — But Not Out! 😤
Earlier this year, we added Pacific Biosciences of California Inc. (Nasdaq: PACB) to our Gold Tier model portfolio.
Since we added PACB 0.00%↑, its stock price has continued to decline — even by as much as a 50% drop since last week.
We’re down . . . but not out!
PACB 0.00%↑ is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome — and, ultimately, resolve genetically complex problems.
It operates in one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis.
It also has the Revio system, a sequencing platform designed for long-read sequencing.
This is an advancement in PACB 0.00%↑'s sequencing technology, aimed at delivering highly accurate long reads of DNA molecules.
The 50% drop in stock price was triggered after PACB 0.00%↑ announced preliminary Q1 2024 revenue and updates.
These results came in below original expectations.
Revenue was flat with $38.8 million.
That’s because PACB 0.00%↑ saw an increasing number of customers delay instrument purchases and experienced some unexpected softness in consumable shipments.
In the last few weeks of March, several Revio system purchases were canceled, which the company believes resulted primarily from elongated customer purchasing cycles.
PACB 0.00%↑ expects these factors to have an impact on its 2024 performance and will provide further details on its full-year outlook in its earnings call scheduled for May 9.
Looking Ahead 👀
Despite all of this, we believe PACB 0.00%↑ is moving forward!
First, it’s improving commercial execution to drive adoption of both the Revio and Onso platforms.
Second, the company is continuing the development of benchtop long-read and high throughput short-read platforms.
Third, it’s implementing projects to improve gross margin and drive manufacturing efficiencies.
And fourth, it’s reducing annualized run-rate operating expenses on a non-GAAP basis by $50 million to $75 million by the end of 2024.
Despite the near-term headwinds, PACB 0.00%↑ continues to see new customers adopt Revio.
This is evidenced by the fact that nearly 60% of system placements in the quarter were accounted for by new customers.
PACB 0.00%↑ also expects consumables to return to sequential growth going forward this year as it continues to grow the Revio installed base.
Additionally, Revio utilization in March was at an all-time high, including some of its top customers exceeding expectations.
PACB 0.00%↑ now expects 2024 revenue to be in the range of $170 million to $200 million. The company believes that second quarter revenue will improve over the first quarter.
It also stated that the second half of the year will improve sequentially as consumables return to sequential growth and it closes some of the deals that were delayed in the first quarter.
Given the company's lowered outlook for 2024, PACB 0.00%↑ believes it’s unlikely to achieve its long-term revenue guidance of at least $500 million in 2026.
Consequently, it's reevaluating the timing of achieving it.
PACB 0.00%↑ now trades at 2X the price-to-sales multiple. In our opinion, this is cheap!
If the second half of 2024 goes as PACB 0.00%↑ projects, the stock price could be bid up far higher than its current $1.60 per share and $430 million market cap.
More Where That Came From 🤩
We’ll continue to hold PACB 0.00%↑ in our Gold Tier model portfolio.
We also hold several other biotech companies bringing revolutionary solutions and therapies to market.
To access them, simply click here and join the ATG Digital family today!
Subscriptions start for as little as $9.99.
#GBC100: Tuesday, April 23, 2024
The #GBC100 is up 3.15% today.
Created on September 22, 2022, the #GBC100 is an index/portfolio comprised of opportunity, growth, innovation, and crypto-related investments.
Our goals with the #GBC100 are twofold . . .
First, we want readers to get a sense of what our investments are doing in the market, because they can sometimes perform very differently than traditional indices (like the S&P 500 or Nasdaq 100).
Second, we’d like to eventually turn the #GBC100 into an ETF.
That way, instead of owning hundreds of growth stocks, you can get exposure to ATG Digital thinking — in opportunity, growth, innovation, and crypto — all in one place.
To learn more or to express your support for the launch of an ETF (by completing a poll), click here.
Tomorrow: Dean will cover an EV giant . . . 🚘 Stay tuned!
Today, Paul went live on our YouTube channel to talk about Tesla Inc. (Nasdaq: TSLA) and the new energy sector.
If you missed it, be sure to watch the video below! 👇
On Tuesday, April 23, 2024, we hope you find this information useful!
❤️️ This Substack made — by US, for YOU — with love. ❤️️
Questions? Concerns? 🤔 Look Below 👇
Have questions or trouble accessing your account? Please reach out to us at info@atgdigital.media or schedule a call, and our Customer Support team will be happy to help.
You can also check our FAQ page on our website for an up-to-date list of questions and answers. Your question may have been addressed there.
*Please be advised that customer support calls are limited to 15 minutes and will strictly cover your membership subscription and billing needs only. Any calls that are disrespectful in nature may be subject to immediate termination.
Join us, be #BOP 🚀, be #StrongHands 🙌, #GoATG! ️️❤️️
Disclaimer/Legal Stuff Written in Plain English
What you read/watch/hear is OPINION, not financial/investment advice. Treat it no different than when you read/watch/hear your favorite author/YouTuber/podcaster. Despite our best efforts, we get things wrong and make mistakes. Investing is risky. There is no guarantee you will make money. Your investments may lose value. That’s RISK. Past performance is no guarantee of future results. Employees, contractors, and owners of ATG Digital, LLC own/trade/transact in the stocks, options, and crypto that are the subject of our trade alerts, updates, reports, and commentaries. We cannot give you personalized financial advice because we are NOT financial advisors. It’s on you to decide how much/when/what to buy/sell based on YOUR financial needs, plans, and risk preferences. There are no guarantees. Loss of your capital is an outcome that you should evaluate carefully with a financial advisor before you trade, speculate, or invest. It's your money and your responsibility.
Even George is Selling out to BITCOIN